Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Treating advanced melanoma with ipilimumab and HF10

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.06.17
Views: 1391

Prof Robert Andtbacka - Huntsman Cancer Institute, Salt Lake City, USA

Prof Andtbacka speaks with ecancer at ASCO 2017 about results from a phase II multicenter trial combining intralesionally injected HF10, an oncolytic Herpes virus, with anti-CTLA4 targeted therapy to treat metastatic or unresectable melanoma

He describes the encouraging response rates from the small trial group, with 41% overall response at 24 weeks, significantly more than trials using ipilimumab alone, with many patients experiencing a durable response.

Prof Andtbacka notes pending analysis of patients responses to assess if age and immune senescence may influence these outcomes, and highlights further trials testing HF10 alongside other immune agents, including a similar trial ongoing in Japan.

Intralesional oncolytic therapies were also discussed by Prof Sanjiv Agarwala at EADO 2017 .


Related videos

follow us

Donate to ecancer

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation